Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Diabetic Medicine

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dme.12709PMID 25645049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure

  2014cited by this paper
• Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

  2012cited by this paper
• Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

  2009cited by this paper
• Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications.

  2002cited by this paper
• Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.

  1999cited by this paper
• Metformin kinetics in healthy subjects and in patients with diabetes mellitus.

  1981cited by this paper

• Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?

  2016cites this paper
• Metformin associated lactic acidosis (MALA): clinical profiling and management

  2016cites this paper